Concord Biotech's board of directors has cleared a proposal to roll out its maiden bonus issue, a step that will effectively double the equity share volume held by qualifying shareholders. The decision came through during the board meeting conducted on Wednesday, September 23, under which eligible investors are slated to receive one fresh equity share for every one equity share held on the record date. Both the existing and newly allocated shares carry a face value of Rs. 1 each, though the execution remains subject to shareholder approval.
Capital Expansion and Issue Scale
The proposed 1:1 bonus issue will see Concord Biotech issue 10,46,16,204 new equity shares, translating to an aggregate face value of Rs. 10.46 crore. At present, the company's paid-up share capital stands at Rs. 10.46 crore. Following the full allotment of these additional shares, the total paid-up equity base will expand to Rs. 20.92 crore, significantly broadening the company's equity foundation and expanding circulating liquidity across public markets.
Capitalisation of Share Premium Account
Financially, this corporate action will not involve any cash payout from corporate reserves. Instead, Concord Biotech plans to capitalise Rs. 10.46 crore directly from its share premium account to finance the issuance of these fully paid-up shares. Balance sheet figures show that the company possessed a healthy share premium balance of Rs. 81.97 crore as of March 31, 2026, providing more than adequate cushion to execute this capital reallocation without stretching operational liquidity.
Eligibility Terms and Record Date Awaited
The company has not yet announced the specific record date that will govern investor eligibility. The record date serves as the crucial benchmark determining which equity holders are on the company's register to receive the free allotments. Investors who intend to qualify for the bonus shares must ensure their holdings comply with applicable trading settlement timelines ahead of the designated ex-date and record date. Management will confirm the timetable once formal shareholder clearance is secured.
Impact on Investor Portfolio Value
A bonus issue multiplies the quantity of shares in an account without instantly inflating the underlying portfolio value, as the market price adjusts proportionally on the ex-date. To illustrate the mechanics, consider an investor possessing 100 shares priced at Rs. 1,560 each, creating a total investment valuation of Rs. 1.56 lakh prior to the adjustment. Upon the execution of the 1:1 bonus, that holding doubles to 200 shares. Concurrently, the theoretical adjusted market price halves to approximately Rs. 780 per share, keeping the gross position value unchanged at Rs. 1.56 lakh.
Stock Performance and Quarterly Financials
Trading on the NSE on September 24 saw the company's shares drop 5.15 percent to conclude the session at Rs. 1,480. Despite that daily decline, broader trading patterns show sustained momentum. According to exchange data, Concord Biotech has recorded an appreciation of around 42.6 percent over the previous six months, while generating an advance of roughly 10.76 percent during the calendar year 2026.
Operational results for the quarter ended June 2026 reflect steady business expansion. The company posted consolidated net sales of Rs. 257.49 crore, marking a 26.23 percent increase from the Rs. 203.99 crore reported in the corresponding prior-year period. Profitability mirrored that trajectory, with consolidated net profit climbing 32.84 percent year-on-year to Rs. 58.53 crore. Furthermore, EBITDA moved up by 26.8 percent to touch Rs. 95.20 crore, underscoring solid earnings health leading into this corporate action.
